#	Pagina
attuale pagina	/open-h2020/projects/205008/index.html

Opendata, web and dolomites

Sencell16

Lifecare’s Sencell sensor is an implantable micro-sensor for subcutaneous location, long time, continuous, wireless, real time monitoring of interstitial glucose for diabetes management.

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

Sencell16 project word cloud

Explore the words cloud of the Sencell16 project. It provides you a very rough idea of what is the project "Sencell16" about.

time arm mobile noninvasively sensor hyperglycemia significantly doses signals sensors sugar skin operation material wires pressure improves independently blood reducing encased enzymatic communication contains battery insulin prompting translates cona automatically osmotic monitoring space accurate signal inner interstitial influence medical wrist miniaturized designed transmitter hypoglycemia induce membrane semi cell entire generate reading inside physical sensitivity suitable sencell proprietary cavity biocompatible relayed device utilizes subcutaneous concanavalin fluid subcutaneously substances glucose implanted places dextran intended insertion alternatives protruding unlike longer sites patented covered located autonomously core transducer warning permeable final user enclosed body function

Project "Sencell16" data sheet

The following table provides information about the project.

Coordinator	LIFECARE AS Organization address address: OVRE KRAKENES 17 city: BERGEN postcode: 5152 website: www.lifecare.no contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Norway [NO]
Project website	http://www.lifecare.no
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SMEINST-1-2016-2017
Funding Scheme	SME-1
Starting year	2016
Duration (year-month-day)	from 2016-08-01 to 2016-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	LIFECARE AS LIFECARE AS Organization address address: OVRE KRAKENES 17 city: BERGEN postcode: 5152 website: www.lifecare.no contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NO (BERGEN)	coordinator	50˙000.00

Map

Project objective

The SENCELL Glucose Monitoring System includes an osmotic pressure sensor, transmitter and mobile medical application. The miniaturized sensor is designed to be implanted into the subcutaneous space of arm wrist or other suitable body sites and requires no battery or wires for the sensor operation and for communication with the transmitter. After insertion, the sensor is designed to function noninvasively, automatically, and continuously for a long term duration that is comparable or longer than existing product alternatives.

The miniaturized SENCELL is designed to continuously measure glucose in the interstitial fluid for a long term duration that is comparable or longer than existing product alternatives. Unlike currently used glucose sensors, the Sencell is intended to be implanted subcutaneously on the arm wrist or other subcutaneous places in the body with no sensor part protruding from the skin.

Encased in a biocompatible material, the device utilizes a unique osmotic pressure assessment technology, which translates the signal of a physical miniaturized osmotic pressure cell into an accurate glucose reading that can be used for determination of insulin doses and to generate warning signals in case of hypoglycemia or hyperglycemia development.

The inner core of the device is the unique and proprietary osmotic patented pressure cell, which is covered on one side by a semi-permeable membrane. The membrane is enclosed inside the top of a cavity where the pressure transducer is also located. The cavity contains Concanavalin A and Dextran.

The use of ConA/Dextran as enzymatic component significantly improves the sensitivity to changes in the blood sugar level while reducing the influence from other substances in the blood. In the final product, the measurement is then relayed to the transmitter. The entire measurement is designed to be done autonomously and independently without any prompting by the user. However, the user can induce a measurement at any time

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SENCELL16" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SENCELL16" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

RESHAPE (2019)

Reshaping undesired Inflammation in challenged Tissue Homeostasis by Next-Generation regulatory T cell (Treg) Approaches – from Advanced Technology Developments to First-in-Human Trials